New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis - Business Fast

Recommended For You

Glencore reviews London listing as miners sour on UK market

February 19, 2025Market

Infy’s low pre-hike bonus; Ex-OpenAI CTO’s Thinking Machines

February 19, 2025Technology

APi Group Provides Update on 2024 Performance and Initial 2025 Guidance and Announces Repricing of Term Loan

February 19, 2025Finance

5 worst performing, India-focused offshore equity funds and ETFs in 1 year

February 19, 2025fund

Fed minutes ahead, U.S.-Russia talks, Trump tariff threat – what's moving markets

February 19, 2025US economy

This website uses cookies. By continuing to use this site, you accept our use of cookies.